Anti-Carbonic Anhydrase 9 (CA9/G250) Rabbit Polyclonal Antibody for WB - Q16790

Core Product Specifications and Parameters

Biological Background: Carbonic Anhydrase 9 Function and Localization

• Carbonic anhydrase 9 (CA9/CA-IX) is a member of the alpha-carbonic anhydrase family, encoding a transmembrane zinc metalloenzyme.
• It catalyzes the reversible hydration of carbon dioxide to bicarbonate and protons, playing a critical role in pH regulation.
• CA9 is primarily expressed in carcinoma cell lines, with limited normal tissue expression, most abundant in gastric mucosa epithelial cells.
• It localizes to the cell membrane, microvillus membrane, nucleus, and nucleolus.
• The protein undergoes post-translational modifications including phosphorylation and glycosylation, and contains disulfide bonds.
• Key structural features: signal peptide, transmembrane helix, and zinc-binding site essential for its catalytic activity.
• Molecular weight is approximately 49.7 kDa (UniProt) but often observed at 50 kDa due to glycosylation.

Experimental Guidance and Technical Tips

• The immunogen corresponds to the extracellular domain (aa 52-151); consider testing the antibody in non-reducing conditions for native conformation recognition.
• For Western blot, validate using lysates from hypoxia-treated human carcinoma cells (e.g., HT-29, HeLa); expect a band around 50 kDa.
• IHC-P may require antigen retrieval and titration to detect membrane and/or nuclear staining in tumor samples.
• For IF/ICC, include permeabilization steps to detect intracellular pools and co-stain with membrane markers.
• ELISA performance can be assessed with recombinant CA9 protein; optimize coating and detection conditions.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio provides diagnostic manufacturers and research labs with comprehensive access to IVD raw materials, including validated antibody pairs, optimized monoclonal/polyclonal antibodies, and bulk ancillary reagents. Our carbonic anhydrase 9 offering supports cancer biomarker research and hypoxia-related assay development. Additionally, we facilitate rare target sourcing and technical consultation to accelerate your project from concept to clinic.